https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2019 » January
Prana Biotechnology secures orphan designation for PBT434 in MSA

Prana Biotechnology secures orphan designation for PBT434 in MSA

Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple System Atrophy (MSA). Prana Biotechnology claims that its application was based on the proposed use of the molecule as a treatment for MSA, including the medical and scientific rationale. The Australian biotech company said that […]

AgeneBio enrolls first patient in AGB101 phase 3 trial in MCI due to AD

AgeneBio, a US-based CNS biopharma company, enrolled the first patient in a phase 3 clinical trial to study the efficacy of AGB101 for the treatment of amnestic Mild Cognitive Impairment caused by Alzheimer’s Disease (MCI due to AD). The late-stage trial, known as HOPE4MCI, will enroll a total of 830 patients, aged between 55 and […]

Continue reading …
Spectrum offloads seven hematology/oncology drugs to Acrotech in $300m deal

US biopharma company Spectrum Pharmaceuticals has agreed to offload seven of its FDA-approved hematology/oncology drugs to Acrotech Biopharma, a subsidiary of Aurobindo Pharma USA, in a deal worth around $300 million. The decision to sell the drugs has been taken to focus on new and innovative therapies for cancer patients, said Spectrum Pharmaceuticals. The seven […]

Continue reading …
FDA accepts X-Rx new drug application for IPD drug X-165

US biotech company X-Rx said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for X-165, a small molecule inhibitor of Autotaxin X-165, which is being developed as a new drug for Idiopathic Pulmonary Fibrosis. According to X-Rx, X-165 as an orally delivered agent, has shown promising results […]

Continue reading …
Tamr joins Accenture’s life sciences ecosystem to help drive innovation in drug discovery and scientific research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture’s cloud-based informatics research platform, which has been designed to help life sciences organizations […]

Continue reading …
Clovis PARP inhibitor Rubraca gets EC approval for relapsed ovarian cancer

Rubraca EC approval : US biotech company Clovis Oncology has secured approval for an additional indication for its cancer drug Rubraca (rucaparib) in Europe – as maintenance treatment for adult women whose ovarian cancer has relapsed. The approval from the European Commission (EC) is for the PARP inhibitor to be used as monotherapy for patients […]

Continue reading …
Eusa Pharma acquires iMCD drug Sylvant global rights from Janssen

Eusa Pharma has completed acquisition of the global rights of idiopathic multicentric Castleman’s disease drug (iMCD drug) Sylvant (siltuximab) from Janssen Sciences Ireland in an all-cash deal worth $115 million. The deal was signed in July 2018 by Eusa Pharma in a move to significantly consolidate its footprint as a global biopharma company in oncology […]

Continue reading …
Takeda acquisition of Shire : Japanese pharma company completes $62bn acquisition

Takeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish biotech company with a focus on rare diseases, for $62 billion, as per the latest pharma acquisition news. Takeda acquisition of Shire It was in May 2018 when Takeda agreed to acquire the Irish rare […]

Continue reading …
Lilly to acquire Stamford biopharma company Loxo Oncology in $8bn deal

Lilly acquisition of Loxo Oncology : US pharma giant Eli Lilly and Company (Lilly) has signed an all-cash deal worth $8 billion to acquire Loxo Oncology, a Connecticut-based biopharma company, as per the latest pharma acquisition news. Lilly acquisition of Loxo Oncology The acquisition of Loxo Oncology is expected to expand the scope of Lilly’s […]

Continue reading …
US biotech company Celgene to be acquired by Bristol-Myers Squibb for $74bn

Bristol-Myers Squibb acquisition of Celgene : US biotech company Celgene has agreed to be acquired by Bristol-Myers Squibb in a stock and cash deal worth about $74 billion, as per the latest pharma acquisition news. The merger of the two US pharma companies will form a specialty biopharma company focused on developing high-value innovative medicines […]

Continue reading …